| [1] |
Perou CM,Sørlie T,Eisen MB,et al.Molecular portraits of human breast tumours.Nature,2000,406:747-752.
|
| [2] |
Zhao HJ,Langerod A,Ji Y,et al.Different gene expression patterns in invasive lobular and ductal carcinomas of the breast.Mol Biol Cell,2004,15:2523-2536.
|
| [3] |
Parker JS,Mullins M,Cheang MCU,et al.Supervised risk predictor of breast cancer based on intrinsic subtypes.J Clin Oncol,2009,27:1160-1167.
|
| [4] |
Herschkowitz JI,Simin K,Weigman VJ,et al.Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.Genome Biol,2007,8:R76.
|
| [5] |
Mc Guire WL.Steroid receptors in human breast cancer.Cancer Res,1978,38:4289-4291.
|
| [6] |
Horwitz KB,McGuire WL.Predicting response to endocrine therapy in human breast cancer:a hypothesis.Science,1975,189:726-747.
|
| [7] |
Degenshein GA,Bloom N,Tobin E.The value of progesterone receptor assays in the management of advanced breast cancer.Cancer,1980,46:2789-2793.
|
| [8] |
Sørlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci USA,2003,100:8418-8423.
|
| [9] |
Slamon DJ,Godolphin W,Jones LA,et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science,1989,244:707-712.
|
| [10] |
Rasmussen BB,Regan MM,Lykkesfeldt AE,et al.Adjuvant letrozole versus tamoxifen according to centrallyassessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer:supplementary results from the BIG 1-98 randomised trial.Lancet Oncol,2008,9:23-28.
|
| [11] |
Kaufman B,Mackey JR,Clemens MR,et al.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptorpositive metastatic breast cancer:results from the Randomized Phase III TAnDEM Study.J Clin Oncol,2009,27:5529-5537.
|
| [12] |
Konecny G,Pauletti G,Pegram M,et al.Quantitative association between,HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.J Natl Cancer Inst,2003,95:142-153.
|
| [13] |
Sørlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Nat Acad Sci,2001,98:10869-10874.
|
| [14] |
Rakha EA,Elsheikh SE,Aleskandarany MA,et al.Triple-negative breast cancer:distinguishing between basal and nonbasal subtypes.Clin Cancer Res,2009,15:2302-2310.
|
| [15] |
Young SR,Pilarski RT,Donenberg T,et al.The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.BMC Cancer,2009,9:86.
|
| [16] |
Glinsky GV,Berezovska O,Glinskii AB.Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.J Clin Invest,2005,115:1503-1521.
|
| [17] |
van de Vijver MJ,He YD,van't Veer LJ,et al.A gene-expression signature as a predictor of survival in breast cancer.N Engl J Med,2002,347:1999-2009.
|
| [18] |
Wang Y,Klijn JG,Zhang Y,et al.Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.Lancet,2005,365:671-679.
|
| [19] |
Kang YB,Siegel PM,Shu WP,et al.A multigenic program mediating breast cancer metastasis to bone.Cancer Cell,2003,3:537-549.
|
| [20] |
Pollack JR,Sorlie T,Perou CM,et al.Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors.Proc Natl Acad Sci,2002,99:12963-12968.
|
| [21] |
Gautschi O,Bigosch C,Huegli B,et al.Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.J Clin Oncol,2004,22:4157-4164.
|
| [22] |
Braun S,Vogl FD,Naume B,et al.A pooled analysis of bone marrow micrometastasis in breast cancer.N Engl J Med,2005,353:793-802.
|
| [23] |
Geisler S,Lønning PE,Aas T,et al.Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.Cancer Res,2001,61:2505-2512.
|
| [24] |
Cheang MCU,Voduc D,Bajdik C,et al.Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.Clin Cancer Res,2008,14:1368-1376.
|
| [25] |
Goldstein LJ,Gray R,Badve S,et al.Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.J Clin Oncol,2008,26:4063-4071.
|
| [26] |
Buyse M,Loi S,van't Veer L,et al.Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.J Natl Cancer Inst,2006,98:1183-1192.
|
| [27] |
Fan C,Oh DS,Wessels L,et al.Concordance among gene-expression-based predictors for breast cancer.N Engl J Med,2006,355:560-569.
|
| [28] |
Jordan VC.The 38th David A.Karnofsky lecture:The paradoxical actions of estrogen in breast cancer-Survival or death?J Clin Oncol,2008,26:3073-3082.
|
| [29] |
Lønning PE,Lien E.Mechanisms of action of endocrine treatment in breast cancer.Crit Rev Oncol/Haematol,1995,21:158-193.
|
| [30] |
Harvey JM,Clark GM,Osborne CK,et al.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.J Clin Oncol,1999,17:1474-1481.
|
| [31] |
Lewis JS,Meeke K,Osipo C,et al.Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.J Natl Cancer Inst,2005,97:1746-1759.
|
| [32] |
Ellis MJ,Gao F,Dehdashti F,et al.Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive,aromatase inhibitor-resistant advanced breast cancer:a phase 2 randomized study.JAMA,302:774-780.
|
| [33] |
Zhu L,Chow LW,Loo WT,et al.Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer:subgroup analysis from celecoxib antiaromatase neoadjuvant trial.Clin Cancer Res,2004,10:4639-4644.
|
| [34] |
Ellis MJ,Coop A,Singh B,et al.Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive,estrogen receptor-positive primary breast cancer:Evidence from a phase III randomized trial.J Clin Oncol,2001,19:3808-3816.
|
| [35] |
Smith IE,Dowsett M,Ebbs SR,et al.Neoadjuvant treatment of postmenopausal breast cancer with anastrozole,tamoxifen,or both in combination:the immediate preoperative anastrozole,tamoxifen,or combined with tamoxifen(IMPACT)multicenter double-blind randomized trial.J Clin Oncol,2005,23:5108-5116.
|
| [36] |
Johnston S,Pippen J,Pivot X,et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.J Clin Oncol,2009,27:5538-5546.
|
| [37] |
Piccart-Gebhart MJ,Procter M,Leyland-Jones B,et al.Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.N Engl J Med,2005,353:1659-1672.
|
| [38] |
Kaufman B,Trudeau M,Awada A,et al.Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer:final results and survival of the expanded HER2+cohort in EGF103009:a phase II study.Lancet Oncol,2009,10:581-588.
|
| [39] |
Smith IE,Walsh G,Skene A,et al.A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.J Clin Oncol,2007,25:3816-3822.
|
| [40] |
Wong KK,Fracasso PM,Bukowski RM,et al.A phase I study with neratinib(HKI-272),an irreversible Pan ErbB receptor tyrosine kinase inhibitor,in patients with solid tumors.Clin Cancer Res,2009,15:2552-2558.
|
| [41] |
Baselga J,Cortes J,Fumoleau P,et al.Pertuzumab and trastuzumab:re-responses to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with each agent given separately:a new biological and clinical observation.Cancer Res,2009,69:803S-804S.
|
| [42] |
O'Shaugnessy J,Blackwell KL,Burstein H,et al.A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy.J Clin Oncol,2008,26(15s(Part I)):1015,44s.
|
| [43] |
Normanno N,Bianco C,De Luca A,et al.Target-based agents against ErbB receptors and their ligands:a novel approach to cancer treatment.Endocr Relat Cancer,2003,10:1-21.
|
| [44] |
Junttila TT,Akita RW,Parsons K,et al.Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.Cancer Cell,2009,15:429-440.
|
| [45] |
Migliaccio I,Gutierrez MC,Wu MF,et al.PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer(LABC).Cancer Res,2009,69:71S-72S.
|
| [46] |
Benvenuti S,Frattini M,Arena S,et al.PIK3CA cancer mutations display gender and tissue specificity patterns.Hum Mutat,2008,29:284-288.
|
| [47] |
Karakas B,Bachman KE,Park BH.Mutation of the PIK3CA oncogene in human cancers.Br J Cancer,2006,94:455-459.
|
| [48] |
Bleeker FE,Felicioni L,Buttitta F,et al.AKT1(E17K)in human solid tumours.Oncogene,2008,27:5648-5650.
|
| [49] |
Yonemori K,Tsuta K,Shimizu C,et al.Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.Med Oncol,2009,26:344-349.
|
| [50] |
Liu L,Greger J,Shi H,et al.Novel Mechanism of lapatinib resistance in HER2-positive breast tumor cells:activation of AXL.Cancer Res,2009,69:6871-6878.
|
| [51] |
Berry DA,Cirrincione C,Henderson IC,et al.Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.JAMA,2006,295:1658-1667.
|
| [52] |
Colleoni M,Minchella I,Mazzarol G,et al.Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors.Ann Oncol,2000,11:1057-1059.
|
| [53] |
Vincent-Salomon A,Rousseau A,Jouve M,et al.Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy.Eur J Cancer,2004,40:1502-1508.
|
| [54] |
Penault-Llorca F,Andre F,Sagan C,et al.Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.J Clin Oncol,2009,27:2809-2815.
|
| [55] |
Bartlett JMS,Munro AF,Dunn JA,et al.Predictive markers of anthracycline benefit:a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial(NEAT/BR9601).Lancet Oncol,2010,11:266-274.
|
| [56] |
Ayers M,Symmans WF,Stec J,et al.Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil,doxorubicin,and cyclophosphamide chemotherapy in breast cancer.J Clin Oncol,2004,22:2284-2293.
|
| [57] |
Chang JC,Wooten EC,Tsimelzon A,et al.Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.Lancet,2003,362:362-369.
|
| [58] |
Hannemann J,Oosterkamp HM,Bosch CAJ,et al.Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.J Clin Oncol,2005,23:3331-3342.
|
| [59] |
Potti A,Dressman HK,Bild A,et al.Genomic signatures to guide the use of chemotherapeutics.Nat Med,2006,12:1294-1300.
|
| [60] |
Paik S,Tang G,Shak S,et al.Gene expression and benefit of chemotherapy in women with node-negative,estrogen receptor-positive breast cancer.J Clin Oncol,2006,24:3726-3734.
|
| [61] |
Albain KS,Barlow WE,Shak S,et al.Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive,oestrogen-receptor-positive breast cancer on chemotherapy:a retrospective analysis of a randomised trial.Lancet Oncol,2010,11:55-65.
|
| [62] |
Straver ME,Glas AM,Hannemann J,et al.The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.Breast Cancer Res Treat,2010,119:551-558.
|
| [63] |
Sørlie T,Wang YL,Xiao CL,et al.Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer:gene expression analyses across three different platforms.BMC Genomics,2006,7:l27.
|
| [64] |
Liedtke C,Mazouni C,Hess KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.J Clin Oncol,2008,26:1275-1281.
|
| [65] |
Hugh J,Hanson J,Cheang MC,et al.Breast cancer subtypes and response to docetaxel in node-positive breast cancer:use of an immunohistochemical definition in the BCIRG 001 trial.J Clin Oncol,2009,27:1168-1176.
|
| [66] |
Byrski T,Gronwald J,Huzarski T,et al.Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.J Clin Oncol,2010,28:375-379.
|
| [67] |
Rhiem K,Wappenschmidt B,Bosse K,et al.Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.Clin Oncol,2009,21:448-450.
|
| [68] |
Byrski T,Huzarski T,Dent R,et al.Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.Breast Cancer Res Treat,2009,115:359-363.
|
| [69] |
Silver DP,Richardson AL,Eklund AC,et al.Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer.J Clin Oncol,2010,28:1145-1153.
|
| [70] |
Palacios J,Robles-Frias MJ,Castilla MA,et al.The molecular pathology of hereditary breast cancer.Pathobiology,2008,75:85-94.
|
| [71] |
Edwards SL,Brough R,Lord CJ,et al.Resistance to therapy caused by intragenic deletion in BRCA 2.Nature,2008,451:1111-1115.
|
| [72] |
Fong PC,Boss DS,Yap TA,et al.Inhibition of poly(ADP-ribose)polymerase in tumors from BRCA mutation carriers.N Engl J Med,2009,361:123-134.
|
| [73] |
O'Shaugnessy J,Osborne C,Pippen J,et al.Efficacy of BSI-201,a poly(ADP-ribose)polymerase-1(PARP1)inhibitor,in combination with gemcitabine/carboplatin(G/C)in patients with metastatic triple-negative breast cancer(TNBC):results of a randomized phase II trial.J Clin Oncol,2009,27(18S,part II):Abstr 3,793S.
|
| [74] |
Staalesen V,Falck J,Geisler S,et al.Alternative splicing and mutation status of CHEK2 in stage III breast cancer.Oncogene,2004,23:8535-8544.
|
| [75] |
Smid M,Wang Y,Klijn JG,et al.Genes associated with breast cancer metastatic to bone.J Clin Oncol,2006,24:2261-2267.
|
| [76]] |
Ma XJ,Wang Z,Ryan PD,et al.A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.Cancer Cell,2004,5:607-616.
|
| [77]] |
Lonning PE.Genes causing inherited cancer as beacons identifying the mechanisms of chemoresistance.Trends Mol Med,2004,10:113-118.
|